{"id":302444,"date":"2023-11-30T18:46:11","date_gmt":"2023-12-01T00:46:11","guid":{"rendered":"https:\/\/www.liveaction.org\/news\/?p=302444"},"modified":"2023-11-30T10:13:48","modified_gmt":"2023-11-30T16:13:48","slug":"cdc-report-abortion-pill-prescribed-past-limits","status":"publish","type":"post","link":"https:\/\/archive.liveaction.org\/news\/cdc-report-abortion-pill-prescribed-past-limits\/","title":{"rendered":"CDC report shows abortion pill is being prescribed past FDA limits"},"content":{"rendered":"
<\/div>

The abortion pill is likely being prescribed past the approved U.S. Food and Drug Administration’s (FDA) gestational limit of 70 days\/10 weeks, which could result in failed abortions, according to the latest abortion surveillance published<\/a> by the Centers for Disease Control and Prevention (CDC). This seems to confirm that bad actors within the abortion industry are openly flouting<\/a> the FDA’s approved limit for the chemical abortion pill regimen by prescribing abortion-inducing drugs into the second trimester of pregnancy<\/a>.<\/p>\n

FDA’s Safety Requirements<\/strong><\/p>\n

In 2011, following the deaths of several women<\/a>, the FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) for the abortion pill, mifepristone. At that time, the drug had only been approved<\/a> for use up to 7 weeks of pregnancy<\/a>\u00a0in a regimen along with the drug misoprostol.<\/p>\n

Then, in 2016, the Obama administration FDA weakened the REMS<\/a>\u00a0by\u00a0removing<\/em> the requirements that women or teen girls take the first drug in front of a clinician, in-person, at the location of a certified prescriber. The FDA also removed a requirement that the manufacturer report the drug\u2019s non-fatal adverse events\u00a0<\/em>(complications), and the drug\u2019s allowed use was extended for use on preborn children up to 10 weeks (70 days)<\/a> of pregnancy.<\/p>\n

While the 10-week limit remains in effect to this day, the Biden Administration has expanded<\/a> use of the drug regimen by permanently allowing the drug to be shipped by mail and more recently gutting the REMS further by announcing it would allow retail pharmacies to dispense the drug<\/a>, which they have begun<\/a> doing, according to the generic manufacturer, GenBioPro.<\/p>\n

The FDA left the policing of safety regulations in the hands of the manufacturers of the drug, who benefit from failing to de-certify all bad actors.<\/p>\n